methyl 3-(4-((2-(2-hydroxyethyl)phenyl)ethynyl)phenyl)propanoate | 1206629-63-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl 3-(4-((2-(2-hydroxyethyl)phenyl)ethynyl)phenyl)propanoate
• 英文别名: methyl 3-[4-[2-[2-(2-hydroxyethyl)phenyl]ethynyl]phenyl]propanoate
• CAS: 1206629-63-1
• 化学式: C₂₀H₂₀O₃
• 分子量: 308.377
• InChiKey: TYEOPPAWYDUHJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 3-(4-((2-(2-hydroxyethyl)phenyl)ethynyl)phenyl)propanoate 在 lithium hydroxide monohydrate 、 水 作用下， 以 四氢呋喃 为溶剂， 以79%的产率得到3-(4-((2-(2-hydroxyethyl)phenyl)ethynyl)phenyl)propanoic acid
  参考文献：
  名称：

  Discovery of a Potent and Selective Free Fatty Acid Receptor 1 Agonist with Low Lipophilicity and High Oral Bioavailability

  摘要：

  The free fatty acid receptor 1 (FFA1, also known as GPR40) mediates enhancement of glucose-stimulated insulin secretion and is emerging as a new target for the treatment of type 2 diabetes. Several FFA1 agonists are known, but the majority of these suffer from high lipophilicity. We have previously reported the FFA1 agonist 3 (TUG-424). We here describe the continued structure-activity exploration and optimization of this compound series, leading to the discovery of the more potent agonist 40, a compound with low lipophilicity, excellent in vitro metabolic stability and permeability, complete oral bioavailability, and appreciable efficacy on glucose tolerance in mice.

  DOI：

  10.1021/jm301470a
• 作为产物：
  描述：

  3-(4-乙炔基苯基)丙酸甲酯 、 2-溴苯乙醇 在 copper(l) iodide 、 sodium tetrachloropalladate(II) 、 四甲基乙二胺 、 2-二叔丁基膦-1-苯基吲哚 作用下， 以47%的产率得到methyl 3-(4-((2-(2-hydroxyethyl)phenyl)ethynyl)phenyl)propanoate
  参考文献：
  名称：

  Discovery of a Potent and Selective Free Fatty Acid Receptor 1 Agonist with Low Lipophilicity and High Oral Bioavailability

  摘要：

  The free fatty acid receptor 1 (FFA1, also known as GPR40) mediates enhancement of glucose-stimulated insulin secretion and is emerging as a new target for the treatment of type 2 diabetes. Several FFA1 agonists are known, but the majority of these suffer from high lipophilicity. We have previously reported the FFA1 agonist 3 (TUG-424). We here describe the continued structure-activity exploration and optimization of this compound series, leading to the discovery of the more potent agonist 40, a compound with low lipophilicity, excellent in vitro metabolic stability and permeability, complete oral bioavailability, and appreciable efficacy on glucose tolerance in mice.

  DOI：

  10.1021/jm301470a

文献信息

• [EN] COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：UNIV SYDDANSK

  公开号：WO2010012650A1

  公开（公告）日：2010-02-04

  There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type Il diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.

  提供了一种新型化合物，能够调节G蛋白偶联受体GPR40，包括该化合物的组合物和使用方法，用于控制体内胰岛素水平，治疗II型糖尿病、高血压、酮症、肥胖症、葡萄糖不耐受症和与异常高或低血浆脂蛋白、甘油三酯或葡萄糖水平相关的相关疾病。
• COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES
  申请人：Ulven Trond

  公开号：US20110152315A1

  公开（公告）日：2011-06-23

  There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type I1 diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.

  提供了一种新的化合物，能够调节G蛋白偶联受体GPR40，包括该化合物的组合物以及使用它们的方法，用于控制体内胰岛素水平和治疗诸如2型糖尿病、高血压、酮症酸中毒、肥胖症、葡萄糖耐受性不良以及与异常高或低血浆脂蛋白、甘油三酯或葡萄糖水平有关的相关疾病。
• Compounds for the treatment of metabolic diseases
  申请人：Ulven Trond

  公开号：US08586607B2

  公开（公告）日：2013-11-19

  There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type II diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.

  提供了一些新化合物，能够调节G蛋白偶联受体GPR40，包括这些化合物的组合物，以及它们的使用方法，用于控制体内胰岛素水平，治疗诸如II型糖尿病，高血压，酮症，肥胖症，葡萄糖不耐受和与异常高或低的血浆脂蛋白，甘油三酯或葡萄糖水平有关的相关疾病。
• US8586607B2
  申请人：——

  公开号：US8586607B2

  公开（公告）日：2013-11-19
• Discovery of a Potent and Selective Free Fatty Acid Receptor 1 Agonist with Low Lipophilicity and High Oral Bioavailability
  作者：Elisabeth Christiansen、Maria E. Due-Hansen、Christian Urban、Manuel Grundmann、Johannes Schmidt、Steffen V. F. Hansen、Brian D. Hudson、Mohamed Zaibi、Stine B. Markussen、Ellen Hagesaether、Graeme Milligan、Michael A. Cawthorne、Evi Kostenis、Matthias U. Kassack、Trond Ulven

  DOI：10.1021/jm301470a

  日期：2013.2.14

  The free fatty acid receptor 1 (FFA1, also known as GPR40) mediates enhancement of glucose-stimulated insulin secretion and is emerging as a new target for the treatment of type 2 diabetes. Several FFA1 agonists are known, but the majority of these suffer from high lipophilicity. We have previously reported the FFA1 agonist 3 (TUG-424). We here describe the continued structure-activity exploration and optimization of this compound series, leading to the discovery of the more potent agonist 40, a compound with low lipophilicity, excellent in vitro metabolic stability and permeability, complete oral bioavailability, and appreciable efficacy on glucose tolerance in mice.